Literature DB >> 26493310

Prostate-specific antigen and radiolabelled choline PET/CT for the assessment of response to therapy: synergy or conflicting?

Laura Evangelista1, Emilio Bombardieri2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26493310     DOI： 10.1007/s00259-015-3224-1

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  8 in total

1.  Erratum to: (18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide.

Authors:  Ugo De Giorgi; Paola Caroli; Emanuela Scarpi; Vincenza Conteduca; Salvatore Luca Burgio; Cecilia Menna; Andrea Moretti; Riccardo Galassi; Lorena Rossi; Dino Amadori; Giovanni Paganelli; Federica Matteucci
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-07       Impact factor: 9.236

Review 2.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Authors:  Axel Heidenreich; Patrick J Bastian; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Theodor van der Kwast; Malcolm Mason; Vsevolod Matveev; Thomas Wiegel; Filiberto Zattoni; Nicolas Mottet
Journal:  Eur Urol       Date:  2013-11-12       Impact factor: 20.096

3.  Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients.

Authors:  Orazio Caffo; Francesca Maines; Davide Donner; Antonello Veccia; Franca Chierichetti; Enzo Galligioni
Journal:  Clin Genitourin Cancer       Date:  2014-03-15       Impact factor: 2.872

4.  (11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.

Authors:  Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Riccardo Schiavina; Riccardo Renzi; Marco Borghesi; Piergiorgio Di Tullio; Eugenio Brunocilla; Andrea Ardizzoni; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-09-01       Impact factor: 9.236

5.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Authors:  Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

6.  Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone.

Authors:  Ugo De Giorgi; Paola Caroli; Salvatore L Burgio; Cecilia Menna; Vincenza Conteduca; Emanuela Bianchi; Francesca Fabbri; Elisa Carretta; Dino Amadori; Giovanni Paganelli; Federica Matteucci
Journal:  Oncotarget       Date:  2014-12-15

7.  Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.

Authors:  S Gillessen; A Omlin; G Attard; J S de Bono; E Efstathiou; K Fizazi; S Halabi; P S Nelson; O Sartor; M R Smith; H R Soule; H Akaza; T M Beer; H Beltran; A M Chinnaiyan; G Daugaard; I D Davis; M De Santis; C G Drake; R A Eeles; S Fanti; M E Gleave; A Heidenreich; M Hussain; N D James; F E Lecouvet; C J Logothetis; K Mastris; S Nilsson; W K Oh; D Olmos; A R Padhani; C Parker; M A Rubin; J A Schalken; H I Scher; A Sella; N D Shore; E J Small; C N Sternberg; H Suzuki; C J Sweeney; I F Tannock; B Tombal
Journal:  Ann Oncol       Date:  2015-06-03       Impact factor: 32.976

8.  Visceral disease in castration-resistant prostate cancer.

Authors:  C Pezaro; A Omlin; D Lorente; D Nava Rodrigues; R Ferraldeschi; D Bianchini; D Mukherji; R Riisnaes; A Altavilla; M Crespo; N Tunariu; J de Bono; G Attard
Journal:  Eur Urol       Date:  2013-11-22       Impact factor: 20.096
  8 in total
  1 in total

1.  Prospective evaluation of [11C]Choline PET/CT in therapy response assessment of standardized docetaxel first-line chemotherapy in patients with advanced castration refractory prostate cancer.

Authors:  Sarah M Schwarzenböck; Matthias Eiber; Günther Kundt; Margitta Retz; Monique Sakretz; Jens Kurth; Uwe Treiber; Roman Nawroth; Ernst J Rummeny; Jürgen E Gschwend; Markus Schwaiger; Mark Thalgott; Bernd J Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-17       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.